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Abstract 
This study provides the first proof of the novel application of bismuth oxide as a radiosensitiser. It was 
shown that on the highly radioresistant 9L gliosarcoma cell line, bismuth oxide nanoparticles sensitise to 
both kilovoltage (kVp) or megavoltage (MV) X-rays radiation. 9L cells were exposed to a concentration of 
50 μg.mL−1 of nanoparticle before irradiation at 125 kVp and 10 MV. Sensitisation enhancement ratios of 
1.48 and 1.25 for 125 kVp and 10 MV were obtained in vitro, respectively. The radiation enhancement of 
the nanoparticles is postulated to be a combination of the high Z nature of the bismuth (Z = 83), and the 
surface chemistry. Monte Carlo simulations were performed to elucidate the physical interactions 
between the incident radiation and the nanoparticle. The results of this work show that Bi2O3 
nanoparticles increase the radiosensitivity of 9L gliosarcoma tumour cells for both kVp and MV energies. 
Monte Carlo simulations demonstrate the advantage of a platelet morphology. 
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Physica Medica Highlights 
 
 Bi2O3 nanoceramics are a prime candidate for radioenhancement cancer therapy 
 First published surface area measurement of NPs at 48.7 ± 4.5 cm2.g-1 
 SER of Bi2O3 shown to be 1.48 and 1.25 for 125kVp and 10MV in vitro on 9L 
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This study provides the first proof of the novel application of bismuth oxide as a 
radiosensitiser. It was shown that on the highly radioresistant 9L gliosarcoma cell line, bismuth oxide 
nanoparticles sensitise to both kilovoltage (kVp) or megavoltage (MV) X-Rays radiation. 9L cells 
were exposed to a concentration of 50 μg.mL
-1
 of nanoparticle before irradiation at 125kVp and 
10MV. Sensitisation enhancement ratios of 1.48 and 1.25 for 125kVp and 10MV were obtained in 
vitro, respectively. The radiation enhancement of the nanoparticles is postulated to be a combination 
of the high Z nature of the bismuth (Z=83), and the surface chemistry. Monte Carlo simulations were 
performed to elucidate the physical interactions between the incident radiation and the nanoparticle. 
The results of this work show that Bi2O3 nanoparticles increase the radiosensitivity of 9L gliosarcoma 
tumour cells for both kVp and MV energies. Monte Carlo simulations demonstrate the advantage of a 














































































External X-ray Radiation Therapy is a common treatment for many cancers, which has been used 
extensively for many years. Despite the improvement of this cancer modality [1, 2], there are still 
unwanted side effects which need to be addressed [3]. 
One possible solution to improve the efficacy of X-ray radiotherapy exists in the use of metal 
nanoparticles (NPs) as individual radiosensitising agents. Investigations into gold NPs [4-7] and 
Platinum [8, 9] NPs were performed to quantify the biocompatibility of the proposed nanomaterials. 
The metallic NPs were shown to be radioenhancing under kilovolt (kVp) and megavolt (MV) 
radiation fields, however, they presented two problems. First, there was no guarantee that these 
nanomaterials would be biocompatible on the nanoscale. Studies into pure metal NPs showed that the 
size and morphology of the nanoparticle often resulted in varying degrees of toxicity [10, 11]. Metal 
NPs with diameters below 5 nm can freely diffuse into the nucleus and interact directly to DNA, 
resulting in necrosis [9, 10]. Second, the metals used for radiosensitisation require a high atomic 
number (high Z), and are also heavy metals. It was shown that these NPs induced toxicity as the 
treatment concentrations increased. 
To solve these two issues, high Z nanoceramics, such as the promising tantalum pentoxide 
Ta2O5 [12], have started to be investigated. The Ta2O5 nanoparticle aggregates demonstrated the 
required radiosensitisation provided by the heavy Ta metal, and also the necessary biocompatibility 
thanks to the oxide form. 
Bismuth is a better candidate for high Z radiosensitiser research since it is one of the heaviest 
naturally occurring elements of the periodic table [13]. Bismuth oxide and other bismuth-based 
compounds are also known to be biocompatible [14]. They have been extensively used in many 
medical and cosmetic applications for many years [15]. In addition, Stewart et al [16] showed that 
bismuth oxide nanoparticles could be tailored with different oxygen contents, inducing cell 
proliferation or toxicity. Another paper by Bogusz et al [17] highlighted that a theranostic system 



































































This research is aimed to investigate the novel application of high Z bismuth oxide nanoparticles as 
radiosensitisers for cancer therapy. The bismuth oxide nanoparticles were synthesised and irradiated 
with clinical 125 kVp and 10 MV X-ray beams. The cell clonogenic and internalisation assays were 
then performed. Monte Carlo simulations performed complemented the experimental work providing 
insight into the physical mechanisms behind dose enhancement and the effect of the particle 
morphology on these physical mechanisms.  
 
2. Methods and Materials 
2.1 Experimental 
2.1.1 Synthesis  
The bismuth based compounds were fabricated at the Institute of Superconducting and Electronic 
Materials (ISEM). The biocompatible Bi2O3 nanoparticles were synthesised via the precipitation route 
[16, 18]. Bismuth Nitrate (99.9 %, Sigma-Aldrich, Australia) was dissolved in 70% Nitric acid (50-
70% Merck, Australia), and then 30% Ammonium Hydroxide (Sigma Aldrich, Australia) was added 
in small increments until a white precipitate appeared. This was extracted using a centrifuge and 
washed with deionised (DI) water. The precipitate was transferred to a beaker of DI water and stirred 
continuously for 5.5 hours at 100˚C. The precursor was extracted and washed as before then annealed 
under argon for 4 hours in a tube furnace at 530˚C. 
2.1.2 X-ray diffraction (XRD) 
The Bi2O3 was examined using an Enhanced Mini-Materials Analyser (EMMA) X-Ray 
Diffractometer at 40 kV and 25 mA. The X-ray diffractometer scanned between 20˚
 
and 80˚ at a step 
rate of 2.00˚min
-1
 and step size of 0.02˚. The mean crystalline size was determined using the Scherrer 
equation, while the material phase was extracted from the ICDD database using the Traces software 
[19, 20]. 
 



































































The surface area of the nanoparticles was examined using the methylene blue test due to negative 
effects induced by the drying process of Brunauer Emmet Teller (BET) gas adsorption surface area 
method. Bismuth oxide (100 mg) was dispersed in 50 mL deionised (DI) water and 12 mg of 
Methylene Blue (MB) added. After stirring and leaving overnight, a sample was taken from the stock 
and diluted accordingly for UV-vis analysis. The absorption at 665 nm of the MB solution was 
measured using a Shimatzu 3600 NIR UV-vis Spectrophotometer (Shimadzu, Kyoto, Japan). After 
examination, 4 mg of MB was added to the stock with 5 mL of DI. This was repeated for three days 
until
 
the ideal concentration was determined. The concentrations were converted to weight ratios of 
the adsorbed MB: Bi2O3 and the added MB: Bi2O3. The ratio values were plotted against each other to 
produce the Langmuir curve and the ion replacement concentration point was used to determine the 
specific surface area (SSA) according to the following equation [21]: 
           
   
      
          
 
  
    (1) 
where mMB is the weight of MB added, 319.87 g.mol
-1





), AMB is the accepted surface area of a single adsorbed MB molecule 
(130Å
2
) [21] and ms is the weight of the Bismuth oxide. 
 
2.1.4 Cell internalisation 
Cell internalisation was performed at at the Illawarra Health and Medical Research Institute 
(IHMRI). A LSRII (BD, Franklin Lakes, NJ, USA) Fluorescence Activated Cell Sorting (FACS) flow 
cytometer was used in order to determine the degree of internalisation of the nanomaterials into the 
cultured 9L cells. This was done as part of an oxidative stress assay [16]. The cells were brought to 
90% confluence in T12.5cm
2
 flasks (Falcon®, Corning). Twenty four hours before the procedure, 
2x10
4
 cells were transferred to 5 mL flow cytometer tubes and freshly prepared NP solution was 
added to the designated NP sample tubes, filling to 0.5 mL total volume at 50 µg.mL
-1
. After 24 hours 





































































10 000 events were recorded. The degree of internalisation of the nanomaterials was determined with 
FACSDiva software, assessing both forward and side scatter intensities [17, 22]. 
 
2.1.5 Media preparation 
The 9L gliosarcoma cells were maintained in a T75cm
2
 flask with completed Dulbecco's 
Modified Eagle Medium (c-DMEM) (DMEM from GIBCO, supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% Penicillin and Streptomycin) and incubated at 37 ˚C with 5% (v/v) CO2 [12]. 
 
2.1.6 Determination of Bi2O3 k-edge and optimum kVp radiation 
To optimise the dose enhancement effects of the bismuth oxide the correct filter and beam energy 
needed to be calculated. This optimal energy was the closest to the maximum photon mass absorption 
energy for the bismuth oxide compared to water, maximising the secondary photoelectric particle 
production. Using the Xmudatv1.0.1 program the photo attenuation coefficients for water and bismuth 
oxide were generated based on total mass energy absorption. The ratio between the two curves was 
graphed as a function of energy [12]. 
 
2.1.7 Irradiation with kVp and MV beams 
All irradiation experiments were carried out at the radiation oncology department of the Prince of 
Wales Hospital (Randwick, NSW, Australia). Beam energies of 125 kVp and 10 MV were generated 
by a Nucletron Oldelft Therapax DXT 300 Series 3 Orthovoltage unit (Nucletron B.V., Veenendaal, 
The Netherlands) and an Elekta Axesse
TM
 LINAC (Elekta AB, Kungstensgatan, Stockholm, Sweden), 
respectively.  
Cell culturing and clonogenic assays were performed at IHMRI. The 9L cell culture was brought 
to 90% confluence a day prior to irradiation. 50 µg.mL
-1 
of Bismuth oxide NPs was prepared via 



































































The suspension was added to the cell culture medium of the treated samples for 24 hours while the 
untreated
 
controls were not. For kVp experiments, 9L cells were irradiated in T12.5 cm
2
 flasks (BD 
Falcon 
TM
) with 6 mm of medium. For MV experiments, T12.5 cm
2
 flasks were completely filled with 
Hank's Balanced Salt Solution (HBSS). No air bubbles were present inside the flask to ensure that 
electronic equilibrium was obtained at cell monolayer depth. All doses (1, 2, 3, 5, & 8 Gy) were 
delivered in single fractions at room temperature. Tissue culture flasks were laid horizontally and 
surrounded sides and back by a 30x30x10 cm
3
 solid water phantom to ensure backscattering effects 
were taken into account. The flasks were then irradiated with the source perpendicular (z-axis) to the 
flasks. Irradiated flasks of the same dosage were irradiated together to reduce individual dose 
variation. Non-irradiated control samples, with and without bismuth oxide NPs, were handled under 
the same conditions as the irradiated samples [12]. The experiments were performed in triplicate with 
multiple repetitions. 
 
2.1.8 Clonogenic cell survival assay 
Clonogenic assay was used as the radiobiological endpoint to assess the effects of 50 g.mL
-1
 
concentration of bismuth oxide NPs on cell survival, compared to control (no NPs). After irradiation, 
cells were sub-cultured at low density into 100 mm diameter Petri dishes (Sigma) with 10 mL c-
DMEM and incubated for 15 doubling times. Following this, each dish was washed with 5 mL PBS 
(with calcium and magnesium ions) and fixed and stained with 5 mL of a (25% crystal violet, 75% 
ethanol) solution. Colonies consisting of no less than 50 cells were counted (n) and compared with 
initial seeding values (I) to obtain the plating efficiency (PE) [12, 16], expressed as:  
PE =n/I     (2) 
For each group, the surviving fraction (SF) is determined as the ratio of the PE of the irradiated 
sample (PEx) by PE of the non-irradiated control (PEc): 




































































2.1.9 Cell survival analysis 
Survival curves were fit according to the linear quadratic model (LQM) using the associated error 
bars of each point as weighting factors. The LQM describes cell surviving fraction (SF) 
mathematically as a function of absorbed dose (D). The fit parameters, α (Gy
-1
) and β (Gy
-2
), are 
indicative of cell radiosensitivity and repair effectiveness, respectively [7]. They are derived from the 
LQM equation (4): 
                       (4) 
We quantified the degree of dose enhancement introduced by the NPs by means of the 
Sensitisation Enhancement Ratio (SER), defined as the ratio of doses giving 10% cell surviving 
fraction. SER represents a radioenhancement based on the radiobiological endpoint from the LQM 




2.2  Monte Carlo Simulation 
Simulations were performed using Geant4 (version 9.6 patch 2), a Monte Carlo code modelling 
particle transport through matter [23], at the Centre for Medical and Radiation Physics (CMRP). The 
simulation set-up was modelled to retain the essential characteristics of the experimental 
configuration necessary to investigate the physical mechanisms behind the results of the cell 
experiments and to investigate the effect of the shape of the NP aggregate on the energy deposition 
enhancement.  
The geometry consisted of a cell population modelled as an array of spherical water cell volumes 
with 10 µm diameter (shown in Figure 1), placed in a water phantom at a depth of 6 mm and 25 mm 
for kVp and MV beams, respectively, to obtain electronic equilibrium. The dimensions of the 
phantom reflect the sizes of the real phantom used in the experiments. Geant4 Low Energy 
electromagnetic physics was used with Penelope models to describe the interactions of particles down 
to 100 eV in the cell population. Atomic deexcitation processes (including both fluorescence and 



































































The NP aggregate was modelled as a sphere of 10 µm diameter, a cube with 10 µm sides or a 
plate with dimensions 10 µm x 10 µm x 1 µm, placed at the centre of the cell populations, as shown in 
Figure 1. 
The energy spectra of 125 kVp and 10 MV X-ray beams were simulated using SpekCalc v 1.1 
[24] and provided by ARPANSA [25], respectively. A 100 µm x 100 µm beam of photons was 
incident normally on the phantom edge, along the Z axis (see Figure 2). A total of 6 x 10
6
 and 3.5 x 
10
6
 primary photons were incident on the phantom in order to achieve sufficient statistical results in 
the kVp and MV beam simulations, respectively.  
The energy deposited in each cell was calculated with and without the NP.  In this study, the dose 
enhancement factor (DEF) was defined as a ratio DNP/DC*, where DNP and DC* are the doses 
calculated with and without the Bi2O3 NP aggregate placed in the cell array, as shown in Figure 1. 
Water substituted Bi2O3 in the simulation configuration without the NP. The DEF represents the 
physical dose enhancement due to the interactions of incident photon beam and the NP, and is 
independent of delivered dose. 
The DEF was calculated for the different shapes of the NP nanomaterial under study. This factor 
depends on the mass and shape of the NP aggregate. In order to isolate the effect of the increasing 
mass of the NP aggregates, the DEF was scaled with respect to the NP aggregate mass. The scaled 
DEF, referred to as DEFS, was calculated as DEF/mNP where mNP is the mass of the NP aggregate 
placed in the cell population. In order to evaluate the effect of the NP aggregate shape (in terms of 
increasing surface area to volume ratio), the DEF and DEFS were compared. 
The spectra and the Linear Energy Transfer (LET) of secondary electrons produced by the 







































































The bismuth oxide nanoparticles were characterised as alpha phase [26]
 
by the XRD spectrum. 
The Scherrer equation was applied to the three peaks (1 2 0), (2 0 0), and (-2 2 1) which showed the 
Bi2O3 nanoparticles had a size range of range of 50 – 70nm.  This can be observed in Figure 3, 
denoted by the transparency of the platelets. 
 
3.1.2 Surface area 
The optimal MB concentration for the 100 mg of bismuth oxide nanoparticles was determined to 
be 0.26 ± 0.02 mg.mL
-1
. Using the cation replacement point, the surface area of the NPs was 




. There is currently no literature value for comparison. Correct 
sonication played a crucial role in this process due to the tendency of the nanoparticles to aggregate. 
 
3.1.3 Cell internalisation 
The comparison of side scatter (SSC) v.s. forward scatter (FSC) light values at 24 hours showed a 
dramatic increase in the side scatter of the NPs samples over the control. The SSC is proportional to 
the cell granularity and can be used to examine the cellular uptake of the nanoparticles [27]. The 
relative increase in scatter is 7 times higher than the controls indicating that a large quantity of 
nanoparticles had been taken into the cells, as denoted by the dramatic change in scatter distribution 
(Figure 4). 
 
3.1.4 kVp energy determination 
The maximum differential absorption energy is around 40 keV with the K-edge being located at 
91 keV (Figure 5). These values were then examined against the available spectra for the kVp 
orthovoltage unit at Prince of Wales Hospital and it was determined that filter 4 would be the most 
suitable. Filter 4 is an additional filtration of 0.1 mm Cu and 0.25 mm Al; in combination with an X-
ray tube potential of 125 kVp orthovoltage beam, it produces photons with an effective energy of 46.7 




































































3.1.5 Intrinsic toxicity, survival curves, and radiosensitivity parameters 
The Bi2O3 NP used in this experiment underwent argon annealing and were found to have no 
cytotoxicity on 9L cells as previously described [16]. The first radiation energy examined was 125 
kVp, which corresponds to the calculated optimum energy of Bi2O3 (see Figure 5), and is used for 
treatment of superficial cancers. The extracted α and β parameters from the linear quadratic curves 
were 0.075 ± 0.040 Gy
-1
 and 0.017 ± 0.006 Gy 
-2
 for the control sample and 0.355 ± 0.003 Gy
-1
 and 0 
Gy
-2
 for the cells with Bi2O3. This lead to an SER of 1.48 for the Bi2O3 NP at 125 kVp, demonstrating 
that the material is a highly effective radiosensitiser (Figure 6).  
The effect of bismuth oxide nanoparticles was also examined with 10 MV radiation to 
investigate how effective it would be for treating deeper seeded cancers, like brain cancer (Figure 7). 
The extracted α and β parameters from the linear quadratic curves were 0.150 ± 0.030 Gy
-1
 and 0.013 
± 0.005 Gy 
-2
 for the control sample and 0.256 ± 0.054 Gy
-1
 and 0.009 ± 0.007 Gy
-2
 for the cells with 
Bi2O3. The analysis of the curves produced an SER of 1.25 for the Bi2O3 nanoparticles.  
 
3.2 Results of the simulation study 
3.2.1 Effect of NP aggregate geometry in dose enhancement 
The physical dose enhancement produced by the Bi2O3 sphere, cube, and plate placed in the cell 
population was calculated in terms of DEF and DEFS as explained in the Methodology section. Figure 
8 shows the DEF and DEFS in cells with respect to radial distance from NP centre in cell layer 3, 
downstream of the NP, and cell layer 2, containing the NP, in the 125 kVp X-ray field. 
Table 1 shows the total DEF and DEFS obtained when considering the three alternative Bi2O3 NP 
aggregate geometries. It can be observed that the DEF obtained in the case of a cube is larger than that 
of the sphere and plate configurations, however, when the DEFS is considered, the plate geometry is 
superior in terms of dose enhancement. This is due to the higher surface area to volume ratio in the 
case of the plate (2.4 x 10
6



































































(both equal to 0.6 x 10
6
). Since the in vitro conditions assume a monolayer of cells at the time of 
irradiation, the cells in the bottom layer (layer 3 in Figure 1) below the NP aggregate are also shown 
in Table 1.      
 
3.2.2 Secondary electron spectra 
The kinetic energy and LET spectra of secondary electrons entering all the cells in the population 
were analysed to assess the change in the quality of the secondary electrons due to the presence of 
each NP aggregate shape. The results are shown for the kVp and MV beam in Figure 9 where the 
spectra are shown per incident photon on the water phantom. It can be observed that the secondary 
electron spectra and LET are not significantly enhanced by the Bi2O3 NP in the 10 MV photon field. 
This is in contrast to the kilovoltage case where there is a clear enhancement of the secondary electron 
production. In particular, the greatest increase in number of secondary electrons is observed in the 
case of the cube geometry, followed by the sphere and plate.  
These secondary electron spectra results agree with the DEF reported in Table 1 for the 125 kVp 
and 10 MV photon fields, respectively. The enhancement of secondary electron production is 
dependent on the geometry with the cube geometry providing the highest number of secondary 
electrons due to the absolute increase in the mass of Bi2O3 NP material placed in the cell population.  
When the DEFs is calculated, it is observed that the plate geometry is the most efficient enhancer.  
This is due to the increased chance of secondary electrons to be absorbed within the NP aggregate 
itself with increasing geometrical size and lower surface area to volume ratio. The plate geometry 
allows more electrons to escape the surface, as the thickness of the plate is only 1 µm, and the range 
of which is less than the range in Bi2O3 of a 12 keV electron [28], meaning most of the electrons will 
be able to escape the NP geometry. By contrast, the range of a 50 keV electron in Bi2O3 is 10.6 µm 
which means that electrons originate in the cube with energy lower than this value will have a reduced 





































































The MB surface area method provided two advantages over the BET. The first was that the 
suspension was a closer match for the liquid cell environment, closer simulating the actual particle 
size found during testing. The second was that in suspension, the full surface area could be measured 
as the nanoplatelets aggregate when dried and lose access to the majority of their surface area.   
Cell internalisation measurement showed that the nanoparticles were highly internalised after 24 
hours (Figure 4). However, due to the physical parameters of the nanoparticles, the Bi2O3 NPs should 
not penetrate the nucleus and interfere with the DNA resulting in NP induced apoptosis, as is the case 
of nanoparticles with diameters smaller than 5 nm [10].  
Both Geant4 simulations and in vitro experiments were essential for this study. The simulations 
provided insight into the physical processes behind physical dose enhancement in the cells, whereas in 
vitro measurements allowed the study of the synergy among physical, chemical, and biological 
mechanisms when enhancing radiotherapy treatment by means of nanoparticles. 
The Geant4 simulations demonstrated that in the kVp X-ray field, Bi2O3 had considerable 
physical dose enhancement properties, with a dependence on the NP aggregate geometrical shape, 
related to Surface Area to Volume ratio (SA/V). The dose enhancement was shown to be significant 
(DEF around 2-3 in the cell population studied, depending on the geometry of the nanoparticle 
aggregate) in the 125 kVp photon field compared to no significant dose enhancement calculated in the 
10 MV field. This is due to the strong increase in photoelectric effect cross-section in the kVp energy 
range for high Z materials, whereas, electron pair production dominates at 10 MV with contributions 
from Compton scattering. This effect is caused by the strong Z-dependence (approximately power 3-
4) of the photoelectric effect compared to pair production (above 1.022 MeV), which has mass 
attenuation coefficient approximately proportional to Z, and Compton scattering, which is not 
strongly Z-dependent [29]. This means that the higher energy photons in the 10 MV spectra are 
unlikely to strongly contribute to radiation dose enhancement. The megavoltage simulation study 
found no significant enhancement for any NP morphologies studied. The simulation results for Bi2O3 




































































The cell survival curves (Figures 6 and 7) showed that the bismuth oxide has an SER of 1.48 and 
1.25 in kVp and MV beam, respectively. The highest SER values for Au NPs is an enhancement of 
1.41 obtained at 150 kVp on a less radioresistant cell line. The SER reduced when the Au NPs were 
examined in more resistant cells [5]. Tantalum oxide has shown an SER of 1.33 on 9L cells at 10MV 
[12]. The DEF observed in the simulated cell population was 1.87 ± 0.01 in the layer of cells below 
the Bi2O3 NP plate in the 125 kVp X-ray field. This is a DEF calculated in a small number of cells 
close to the NP aggregate in this simulation and cannot be compared directly to the experimental 
SERs observed. However, the High-Z dose enhancement properties of Bi2O3 NPs are an important 
factor influencing increased SER and the calculated DEF from the Monte Carlo simulation reflects 
this. 
The effectiveness of any nanoparticle system in radiation fields is due to a number of factors 
including cell line, radiation energy, particle morphology, subcellular localisation, and concentration. 
The 9L gliosarcoma cells used in this study are known to be more radio-resistant and more hypoxic 
than most of other cancerous cells. Oxygen levels in cells have been shown to alter the effectiveness 
of radiation therapy, as oxygen is responsible for indirect damage through radiation induced radicals 
[31]. Therefore, observations on 9L cells should be amplified on less radio-resistant and hypoxic cells. 
The surface chemistry of the nanoparticles also has an important effect on the effectiveness of the 
radiosensitiser as indirect damage is the major mechanism behind cancer apoptosis in radiation 
therapy [32].  It has been shown that nanoparticles can demonstrate catalytic behavior under radiation 
fields becoming radiocatalysts. In the case of our NPs, it is hypothesized that the energy of the 
photons excite the NPs, causing them to act as radiocatalysts and split water molecules into HO˙ and 
H˙ radicals [33]. This produces additional ROS which increases the effectiveness of the 
radiosensitiser and would not be predicted in simulations.  
The morphology (SA/V) of the radiosensitising NPs also plays an important role in their 
effectiveness. The Monte Carlo simulations were designed to model the experimental set up, as stated 
in section 2.2, with the incident x-ray beam along the Z-axis. Each 10μm diameter cell within the 



































































internalisation assay demonstrated high levels of NP internalisation 24 hours after NP exposure within 
the biological cell monolayer (section 3.1.3.), with the incident x-ray beam passing along the z-axis, 
perpendicular to the cell monolayer (section 2.1.7). The Monte Carlo simulations demonstrated that 
the platelet morphology of Bi2O3 NP aggregates leads to more effective radiation damage, especially 
in kVp photon field, due to a larger SA/V ratio compared to the other morphologies as demonstrated 
by our Monte Carlo simulations in section 3.2. Therefore, according to the local effect model the 
platelet morphology leads to a more preferential dose spike distribution in the individual cellular 
environments for the same weighted concentration of NPs.  
The apparent disparity between the Monte Carlo simulations and the in vitro survival curves can 
be explained through a comparison of the analysis techniques [34]. DEF calculations are the physical 
ratio of energy deposited with a NP aggregate compared to a pure water phantom. This produces DEF 
values which are independent of therapeutic dose for a given X-ray energy, i.e. 125 kVp or 10 MV. 
Alternatively, the SER is a radiobiological endpoint based on a quadratic exponential equation (eqn 
4), with the radioenhancement being dependent upon the dose for a given X-ray energy, as seen in 
Figures 6 and 7, and does not scale linearly.  
The Local Effect Model (LEM) for radiation enhancement assists in describing the NP-radiation 
interactions in the biological context. It states that the dose enhancement of a single particle is 
effective only to a small subvolume of the total, i.e. the cytoplasm of a cell with an internalised NP. 
As shown in the Monte Carlo simulations, 50 keV electron has a range of up to 10.6 µm, meaning the 
subvolume affected by the NP under radiation is confined to the inside of a cell, given the average 
diameter of a eukaryotic cell is approximately 20-50 µm. Each subvolume produces a slight variation 
in the dose determined by the NP’s interaction with the incident radiation field (dose spike 
distribution) [32]. While the amplitude and shape of the local dose spikes is different in the kVp and 
MV photon fields due to the LET of the radiation fields [35], both lead to a large SER. The physical 
dose enhancement is the cumulative effect of these NP-radiation field interactions, and produce the 




































































This work provided the first in vitro study of the radiosensitising capacity of bismuth oxide 
nanoparticles on the highly radioresistant 9L gliosarcoma cells. The XRD and MB analysis showed 
that the nanoparticles have a platelet morphology with a thickness of 50 – 70nm and a surface area of 




. The Bi2O3 NP were irradiated with 125 kVp and 10 MV x-ray beams, producing 
SERs of 1.48 and 1.25 respectively. These values are resultant from a combination of the high Z of 
the bismuth, radiocatalytic activity, and the favourable dose distribution resulting from the 
advantageous geometrical shape of the nanoparticles on the highly radioresistance 9L cells.  
Monte Carlo simulations are a valuable tool to examine the physical dose enhancement of NP 
enhanced radiotherapy and the importance of careful simulation design to accurately model NP 
geometry has been demonstrated. Simulations showed that the platelet morphology per unit of Bi2O3 
mass, is the most effective for enhancing the dose, compared to the cubic and spherical morphologies. 
The DEF reported by the simulation study are lower than the biological SER found by means of the 
cell survival experiments in both the kVp and MV radiation fields due to the non-linear dose 
enhancement nature of biological systems. The means that the physical dose enhancement induced by 
the High-Z of Bi2O3 is only one of multiple factors influencing the sensitisation and this is the only 
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Figure 1: Cross-section in y-z plane of cell population with the NP modelled as a sphere (A), cube (B) 
or a plate (C) with the photon beam incident on the cell layer from the left along the Z axis.  D: Cross-
section in x-y plane through layer 2 of cells arrayed around 10 μm diameter sphere of Bi2O3. 
 
Figure 2: 150 kVp (A) and 10MV (B) photon energy spectra, provided in terms of relative frequency 
per incident photon [26]. 
 
Figure 3: High resolution – transmission electron microscopy (HR-TEM) image of Bi2O3 
nanoparticles platelets. 
Figure 4: Nanoceramic internalisation, Side scatter (SSC) of 9L cells without (A) and with (B) 
nanoceramic 
 
Figure 5: Ratio of mass energy absorption coefficient of Bi2O3 relative to water 
 
Figure 6: Survival curves of 9L untreated and treated with 50 μg/ml of Bi2O3 nanoparticles and 
exposed to 125kVp x-ray radiation doses. Surviving fractions were normalised against the non-
irradiated controls, averages taken from a sample size of 3 and errors given ± 1 standard deviation 
from the mean.  
Figure 7: Survival curves of 9L cells untreated and treated with 50 μg/ml of Bi2O3 nanoparticles and 
exposed to 10 MV x-ray radiation doses. Surviving fractions were normalised against the non-
irradiated controls, averages taken from a sample size of 3 and errors given ± 1 standard deviation 
from the mean.  
Figure 8: Radial DER (A & C) and DERS (B & D) in layer 3 (A & B) and layer 2 (C & D) in 125 kVp 
photon radiation field with Bi2O3 NP material in different geometrical configurations (Sphere, Cube, 
Platelet). 
 
Figure 9: Kinetic energy and LET spectra of secondary electrons entering cells in the array with 125 
kVp photon field, (A) and (B), and 10MV photon field, (C) and (D). Bi2O3 sphere (grey circles) 
compared to cube (black circles), plate (crosses) and water (hollow circle). 
 
Table 1: DER and DERS due to each NP aggregate configuration with 125 kVp and 10 MV incident 
photon fields. DER is calculated for the entire cell population and for the cells in layer 3 of the cell 
population (below the NP aggregate) to represent the monolayer of cells seen in cell survival 
experiments. 
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